Company Announcement

Ropren Study Published By Global Leading Peer Reviewed Journal

The Board of Solagran Limited (Solagran) are pleased to announce the recent publication by Phytomedicine of a study of Ropren in ameliorating cognitive deficiency in animal models.

The article is titled “Ropren is a polyprenol preparation from coniferous plants that ameliorates cognitive deficiency in a rat model of beta-amyloid peptide-(25-35)-induced amnesia” J. Fedotova et al

An excerpt from abstract: “After four weeks Ropren treatment significantly improved non-spatial and spatial learning in rats with β-amyloid peptide-(25-35)-induced amnesia. The results of the present study suggest that Ropren, a novel plant preparation, ameliorates cognitive deficiencies in an animal model relevant to Alzheimer’s Disease”.

The article was published online by Phytomedicine: International Journal of Phytotherapy and Phytopharmacology. Phytomedicine is a global, leading peer-reviewed journal specialising in the review of drugs of natural origin. It is widely read by researchers and medical practitioners in this field. It is also a journal of choice for regulatory authorities in assessing suitability of phytomedicines for registration. Phytomedicine is published by Elsevier for the European Scientific Cooperative on Phytomedicine (ESCOP).

Solagran’s Executive Chairman, Dr Vagif Soultanov said: “While the encouraging results of this study will be no surprise to the followers of our scientific program, we accept the need to increasingly put forward our research to leading English language peer-reviewed journals. With additional research now submitted for English peer-reviewed publication, we anticipate a snowballing of scientific interest from outside of Russia, particularly given the communities’ growing concern about the safety of allopathic medicines and accompanying side effects. We are also pleased that just recently Solagran received a report from Russia’s ‘Federal Authority for Surveillance of Healthcare and Social Development’ stating that it has not received a single report of adverse reactions, potential adverse reactions or therapeutic inefficacy for Ropren during the three year period of drug monitoring”.
In conclusion, this study provides further evidence that Solagran’s registered pharmaceutical Ropren is a most unique hepatoprotector due to the nature of this class of substance and its effect on the metabolic pathways in the human body. It not only protects and rejuvenates the liver but also has significant positive impact on the central nervous system, memory and memory decline. Human trials conducted with the Brain Institute at Swinburne University in 2006 to determine Ropren’s effect on improving cognitive function further support the claims. The preliminary results indicated that treatment with Ropren led at the very least to a 15 percent improvement in memory function and speed of recall (refer ASX Announcement 8 November 2006).

Yours faithfully

[Signature]

Justyn Stedwell
Company Secretary
On behalf of the Board of Directors
Solagran Limited